- Home
- SMA vs GLPG Comparison
SMA vs GLPG Comparison
Compare SMA & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMA
- GLPG
- Stock Information
- Founded
- SMA 2013
- GLPG 1999
- Country
- SMA United States
- GLPG Belgium
- Employees
- SMA N/A
- GLPG N/A
- Industry
- SMA
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- SMA
- GLPG Health Care
- Exchange
- SMA NYSE
- GLPG Nasdaq
- Market Cap
- SMA 2.0B
- GLPG 1.9B
- IPO Year
- SMA 2025
- GLPG 2005
- Fundamental
- Price
- SMA $36.26
- GLPG $30.51
- Analyst Decision
- SMA Strong Buy
- GLPG Sell
- Analyst Count
- SMA 7
- GLPG 4
- Target Price
- SMA $39.43
- GLPG $25.33
- AVG Volume (30 Days)
- SMA 1.1M
- GLPG 238.0K
- Earning Date
- SMA 08-07-2025
- GLPG 07-23-2025
- Dividend Yield
- SMA 4.34%
- GLPG N/A
- EPS Growth
- SMA N/A
- GLPG N/A
- EPS
- SMA N/A
- GLPG N/A
- Revenue
- SMA $235,799,000.00
- GLPG $311,493,731.00
- Revenue This Year
- SMA $66.15
- GLPG $0.78
- Revenue Next Year
- SMA $8.99
- GLPG N/A
- P/E Ratio
- SMA N/A
- GLPG N/A
- Revenue Growth
- SMA 5.34
- GLPG 18.32
- 52 Week Low
- SMA $29.89
- GLPG $22.36
- 52 Week High
- SMA $37.79
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- SMA N/A
- GLPG 69.05
- Support Level
- SMA N/A
- GLPG $28.21
- Resistance Level
- SMA N/A
- GLPG $30.64
- Average True Range (ATR)
- SMA 0.00
- GLPG 0.51
- MACD
- SMA 0.00
- GLPG 0.25
- Stochastic Oscillator
- SMA 0.00
- GLPG 96.23
About SMA SMARTSTOP SELF STORAGE REIT INC
Smartstop Self Storage REIT Inc operates as a real estate investment trust. The trust owns, acquires, and operates self-storage properties. It operates in two segments namely, self-storage operations which generates key revenue, and managed REIT platform business. The investment objective is to focus on investing in self-storage facilities and related self-storage real estate investments that are expected to support sustainable stockholder distributions over the long term.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.